A new forensic toxicology study has documented the detection of etomidate in 898 urine samples from suspected drug users in Singapore, highlighting an emerging challenge for laboratories investigating substance misuse.
Published online on 12 November 2026 in the Journal of Analytical Toxicology, the research was conducted by Ching Yee Fong and Hooi Yan Moy of Singapore's Health Sciences Authority.
Etomidate is an ultra-short-acting, non-barbiturate sedative used medically for anaesthesia and sedation. However, its misuse has become a growing concern in parts of Asia, particularly following its incorporation into illicit vaping products.
In Singapore, etomidate was first detected in electronic vaporiser products commonly referred to as "Kpods" in 2024.
The researchers examined toxicological findings from urine samples collected between October 2024 and December 2025 to investigate patterns associated with etomidate misuse.
During this period, etomidate was detected in 898 urine samples obtained from suspected drug users.
One notable finding was that approximately 41.9% of the etomidate-positive samples contained etomidate as the only detected substance.
This observation provides information about the substances detected in the tested samples. However, it does not establish that the individuals had never consumed other drugs or that all possible substances were excluded.
The research also discusses the emergence of structurally related compounds, including metomidate, propoxate, butomidate and CF3-etomidate, following China's classification of etomidate as a controlled drug in October 2023.
The appearance of these analogues creates additional challenges for forensic toxicology laboratories because testing strategies must account for changing patterns of substance misuse.
Forensic toxicologists play an important role in identifying drugs and their metabolites in biological specimens. Reliable analytical testing can support investigations, clinical assessments and public health surveillance.
The Singapore findings demonstrate why laboratories need to monitor emerging substances and regularly evaluate whether their analytical methods remain suitable for detecting compounds of forensic interest.
However, the study has important limitations.
The reported 898 samples represent etomidate-positive specimens from a suspected drug-user population, not a representative sample of Singapore's general population.
Consequently, the results cannot be used to estimate national etomidate-use prevalence.
Additionally, a positive urine result demonstrates detection within the capabilities of the analytical method but does not, by itself, establish the amount consumed, the exact time of administration or the degree of impairment.
The research provides useful evidence of etomidate detection patterns in Singapore and highlights the importance of adapting forensic toxicology testing to emerging substances.
Further surveillance and analytical research may help laboratories respond to changes in the illicit drug market.